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Abstract
Background: The neuropeptide Pituitary adenylate cyclase-activating polypeptide (PACAP) plays pivotal roles in immunity
and inflammation. So far, potential immune-modulatory properties of PACAP have not been investigated in experimental
ileitis.
Methodology/Principal Findings: Mice were perorally infected with Toxoplasma (T.) gondii to induce acute ileitis (day 0)
and treated daily with synthetic PACAP38 from day 1 to 6 post infection (p.i.; prophylaxis) or from day 4 to 6 p.i. (therapy).
Whereas placebo-treated control mice suffered from acute ileitis at day 7 p.i. and succumbed to infection, intestinal
immunopathology was ameliorated following PACAP prophylaxis. PACAP-treated mice exhibited increased abundance of
small intestinal FOXP3+ cells, but lower numbers of ileal T lymphocytes, neutrophils, monocytes and macrophages, which
was accompanied by less ileal expression of pro-inflammatory cytokines such as IL-23p19, IL-22, IFN-c, and MCP-1.
Furthermore, PACAP-treated mice displayed higher anti-inflammatory IL-4 concentrations in mesenteric lymph nodes and
liver and higher systemic anti-inflammatory IL-10 levels in spleen and serum as compared to control animals at day 7 p.i.
Remarkably, PACAP-mediated anti-inflammatory effects could also be observed in extra-intestinal compartments as
indicated by reduced pro-inflammatory mediator levels in spleen (TNF-a, nitric oxide) and liver (TNF-a, IFN-c, MCP-1, IL-6)
and less severe histopathological sequelae in lungs and kidneys following prophylactic PACAP treatment. Strikingly, PACAP
prolonged survival of T. gondii infected mice in a time-of-treatment dependent manner.
Conclusion/Significance: Synthetic PACAP ameliorates acute small intestinal inflammation and extra-intestinal sequelae by
down-regulating Th1-type immunopathology, reducing oxidative stress and up-regulating anti-inflammatory cytokine
responses. These findings provide novel potential treatment options of inflammatory bowel diseases.
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Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP) was
first identified as a hypothalamic neuropeptide stimulating
adenylate cyclase activity in the pituitary gland [1]. The peptide
is a member of the vasoactive intestinal peptide (VIP)/secretin/
glucagon family and shares 68% homology with VIP. Following
alternative splicing from its pre-pro precursor, PACAP is present
in two biologically active amidated forms, namely PACAP27 and
PACAP38 [1,2]. Besides the central nervous system, PACAP is
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widely expressed in peripheral organs of the endocrine, reproduc-
tive, respiratory, and digestive system as well as in lymphoid
organs including immune cells [2]. PACAP exerts its immune-
modulatory functions following binding on three receptors.
Whereas both, VIP and PACAP, can bind to VPAC1 and
VPAC2 receptors present on immune cells such as lymphocytes
and macrophages, PAC1 comprises a receptor specific for
PACAP, which is expressed by macrophages but not lymphocytes
[3–5]. The potent anti-inflammatory properties of exogenous
PACAP have been demonstrated in experimental models of
human arthritis [6] and encephalomyelitis [7], for instance, but
data regarding beneficial effects exerted by synthetic PACAP in
the gut are limited. PACAP2/2 mice subjected to dextran sodium
sulfate (DSS) displayed more severe acute colitis as compared to
wildtype control animals [8,9]. In experimental trinitrobenzene
sulfonic acid (TNBS) induced colitis, VIP exerted prophylactic and
therapeutic effects [10], hence providing evidence for anti-
inflammatory effects of PACAP and VIP in the intestinal tract.
Inflammatory bowel diseases (IBD) such as ulcerative colitis or
Crohn’s disease (also termed ileitis terminalis) are of multi-factorial
etiology and characterized by chronic intestinal inflammation with
acute episodes [11–13]. The vast majority of intestinal inflamma-
tion studies have been performed in colitis models, whereas small
intestinal inflammation in vivo models are scarce.
Within one week following peroral infection with 100 cysts of
the parasite Toxoplasma (T.) gondii, susceptible mice develop
severe small intestinal inflammation (pan-ileitis) and succumb to
infection within seven to ten days. The underlying immunopa-
thology is characterized by an IL-23-induced Th1-type immune
response with a subsequent excessive release of pro-inflammatory
mediators such as IL-22, IL-18, IL-12, IFN-c, TNF-a, and nitric
oxide (NO) [14–19], whereas T. gondii induced counter-regula-
tory cytokines include IL-10 [14,20]. Furthermore, inflammation
is accompanied by distinct shifts in commensal ileal microbiota
composition. Gram-negative species such as E. coli and Bacteroi-
des/Prevotella species overgrow the inflamed ileal lumen during
ileitis development [21], and the inflammatory scenario is further
perpetuated by TLR-4-dependent signaling of lipopolysaccharide
(LPS) derived from intestinal Gram-negative commensals [22,23].
Taken together, the Th1-type immunopathology in the T. gondii-
mediated ileitis model resembles immunopathological key features
of acute episodes in Crohn’s disease [24,25]. Given that the
immune-modulatory properties of PACAP have never been
studied in small intestinal inflammation, we assessed potential
beneficial effects of the synthetic compound in the T. gondii-
induced acute ileitis model. Results reveal distinct time-of-
treatment-dependent anti-inflammatory properties of synthetic
PACAP. Remarkably, PACAP-mediated amelioration of small
intestinal immunopathology was accompanied by systemic anti-
inflammatory effects in extra-intestinal compartments such as
blood, spleen, liver, kidney, and lung.
Methods
Mice, ethical statement
C57BL/6 (wildtype) mice were bred and housed under specific
pathogen-free (SPF) conditions in the Forschungseinrichtung fu¨r
Experimentelle Medizin (FEM, Charite´ – University Medicine
Berlin, Berlin, Germany). All animal experiments were conducted
according to the European Guidelines for animal welfare (2010/
63/EU) with approval of the commission for animal experiments
headed by the ‘‘Landesamt fu¨r Gesundheit und Soziales’’
(LaGeSo, Berlin, registration number G0145/10). Animal welfare
was monitored twice daily by assessment of clinical conditions and
weight loss of mice. Mice suffering from weight loss .20% were
humanely euthanized by isofluran treatment (Abbott, Germany) in
accordance with the guidelines of the local commission for animal
experiments headed by the ‘‘Landesamt fu¨r Gesundheit und
Soziales’’.
Induction of acute ileitis
For induction of acute ileitis, 3 months old female mice were
infected perorally by gavage with 100 T. gondii cysts (ME49 strain)
from homogenized brains of intraperitoneally infected NMRI
mice in a volume of 0.3 ml phosphate-buffered saline (PBS), as
described previously [21,22,26].
Treatment
PACAP38 was synthesized at the Department of Medical
Chemistry, University of Szeged (Hungary), dissolved in PBS and
administered to mice with a daily dose of 1.5 mg per kg body
weight [9]. Mice received the PACAP or PBS (serving as placebo
control, PLC) intraperitoneally (i.p.) in a 0.3 ml volume once daily
starting one day (prophylactic treatment regimen) or four days
(therapeutic treatment regimen) following T. gondii infection until
day 6 post infection. Age- and sex-matched naı¨ve mice served as
negative controls. A potential anti-bacterial effect of the PACAP
solution was excluded as described previously [27].
Sampling procedures, determination of small intestinal
shortening
Mice were sacrificed by isoflurane (Abbott, Wiesbaden,
Germany) seven days after infection. Cardiac blood and tissue
samples from lungs, liver, spleen, kidneys, mesenteric lymph nodes
(MLNs), and terminal ileum were removed under sterile condi-
tions. Intestinal samples were collected for histopathological,
immunohistochemical, and immunological analyses. Small intes-
tinal lengths were determined by measuring the distance from the
duodenum leaving the stomach to the ileal-caecal valve by a ruler.
The relative shortening of the small intestine was calculated by
dividing the difference of the mean length of small intestine from
age- and sex-matched naı¨ve control mice minus the length of
infected mice at day 7 p.i., and then multiplied by 100 over the
mean length of naı¨ve control mice small intestines (relative
shortening in length = (mean d02d7 p.i.)6100/mean d0). Results
were expressed as % shortage.
Histopathology and determination of parasite loads
Histopathological changes were determined in samples derived
from terminal ileum, lungs, and kidneys that were immediately
fixed in 5% formalin and embedded in paraffin. Sections (5 mm)
were stained with hematoxylin and eosin (H&E) and examined by
light microscopy (magnification 1006 and 4006). Histopatholog-
ical changes in the small intestine were quantitatively assessed
applying a standardized histopathological scoring system (ranging
from 0 to 6) for blinded duplicate evaluation as described in detail
earlier [21]. T. gondii DNA was quantified in ileal biospies as
described earlier and expressed in pg [19].
Immunohistochemistry
In situ immunohistochemical analysis of ileum paraffin sections
were performed as described previously [28]. Primary antibodies
against CD3 (#N1580, Dako, Denmark, dilution 1:10), FOXP-3
(FJK-16s, eBioscience, 1:100), myeloperoxidase-7 (MPO-7, #
A0398, Dako, 1:500), and F4/80 (#14-4801, clone BM8,
eBioscience, 1:50) were used. For each animal, the average
number of positively stained cells within at least six independent
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high power fields (HPF, 0.287 mm2; 4006 magnification) was
determined microscopically by two independent double-blinded
investigators.
Real-time PCR
RNA was isolated from snap frozen ex vivo ileum biopsies,
reverse transcribed and analyzed as described previously [19].
Murine IL-23p19 and IL-22 mRNA expressions were detected
and analyzed using Light Cycler Data Analysis Software (Roche).
Expression levels were calculated relative to the HPRT expression
and indicated as ‘‘Arbitrary Units’’.
Detection of cytokine secretion in ex vivo biopsies
Ileal biopsies were cut longitudinally, washed with PBS and
strips of 1 cm2, MLNs, liver or spleen placed in 24-flat-bottom well
culture plates (Nunc, Wiesbaden, Germany) containing 500 ml
serum-free RPMI 1640 medium supplemented with penicillin
(100 U/ml) and streptomycin (100 mg/ml; PAA Laboratories).
After 18 h at 37uC, culture supernatants were tested for IFN-c,
TNF-a, MCP-1, IL-6, and IL-10 concentrations by the Mouse
Inflammation Cytometric Bead Assay (CBA; BD Biosciences) in a
BD FACSCanto II flow cytometer (BD Biosciences). IL-4
concentrations were measured by ELISA (BD Biosciences), and
nitric oxide (NO) was determined by Griess reaction as described
earlier [21].
Statistical analysis
Mean values, medians, standard deviations, standard errors of
the mean, and levels of significance were determined using
appropriate tests as indicated (Mann-Whitney-U test) or the log-
rank test for Kaplan-Meier analysis of survival. Two-sided
probability (p) values #0.05 were considered significant. All
experiments were repeated at least twice.
Results
PACAP treatment prolongs survival in acute ileitis
Following ileitis induction (day 0) T. gondii infected mice were
treated with synthetic PACAP (1.5 mg per kg body weight per day)
via the intraperitoneal route, either from day 1 until day 6
(prophylactic regimen) post infection (p.i.) or starting on day 4,
when first histopathological ileum mucosal changes can be
observed [21], until day 6 following ileitis induction (therapeutic
treatment) and compared to control animals. Given that the
outcome of PLC treated mice was comparable, irrespective
whether the PLC was administered starting by day 1 or 4 p.i.,
derived data were respectively pooled to one PLC treated group as
indicated. Whereas all PLC treated mice had died by day 9.5 p.i.,
80% of mice with PACAP prophylaxis and 40% of mice in the
therapeutic group survived the acute phase of inflammation
(Fig. 1). All mice subjected to short-term PACAP treatment,
however, died until day 11 p.i., whereas by that time 40% of mice
from the prophylaxis group were still alive and 20% survived the
end of the experiment (28 days p.i.; p,0.005 vs. PLC, Kaplan
Meier analysis) (Fig. 1). Thus, PACAP prolongs survival of acute
ileitis when given prophylactically (i.e. before the onset of
histopathological ileal changes).
PACAP ameliorates acute small intestinal inflammation
Within 7 days p.i., PLC-treated control animals developed
wasting disease and lost up to 25% of their initial body weight
whereas mice from either PACAP group displayed significantly
less weight loss (approximately 18%; p,0.001 vs. PLC; Fig. 2A)
indicative for less severe disease. Given that small intestinal
inflammation is accompanied by a significant shortening of the
proximal intestinal tract [21,29,30], we determined the lengths of
the small intestines between PACAP- and PLC-treated mice. Mice
from the PACAP-prophylaxis group exhibited less shrinkage of the
small intestines as compared to short-term PACAP treated and
control mice (p,0.05 and p,0.001, respectively; Fig. 2B).
We next assessed histopathological changes in the ileal mucosa.
Whereas at day 7 p.i. PLC mice displayed severe ileal necrosis
(Fig. 2C, D), mice with therapeutic PACAP treatment, however,
exhibited rather moderate ileal inflammation without necrosis (p,
0.01 vs PLC). Remarkably, mice subjected to PACAP prophylaxis
displayed only mild signs of inflammation as indicated by edema of
the villi and discrete cell-free exudate into the lumen, but intact
epithelium (p,0.0001 vs PLC; Fig. 2C, D). To examine whether
differences in ileal T. gondii loads might have contributed to the
observed beneficial PACAP effects we assessed T. gondii DNA
concentrations in the respective groups. Notably, the amount of T.
gondii DNA in the ileum did not differ between the respective
PACAP-treated and control mice at day 7 p.i. (Fig. S1).
Furthermore, PACAP did not exert any direct anti-bacterial
effects in vitro (not shown). Hence, PACAP-induced changes in
the commensal microbiota composition which in turn might
impact the disease outcome could be excluded.
Taken together, acute ileitis was ameliorated following PACAP
treatment in a time-of-treatment dependent manner as indicated
by significantly higher survival rates, better clinical as well as
histopathological outcome in prophylactically PACAP treated
mice.
Diminished local intestinal inflammation following
PACAP application
We next quantitatively assessed the influx of distinct immune
cell populations into the ileal mucosa of PACAP treated mice by
immunohistochemical staining of ileal paraffin sections. Given that
T cells are the major driving forces of T. gondii-induced acute
ileitis counteracted by IL-10 producing cells such as regulatory T
Figure 1. Survival rates of PACAP treated mice. Ileitis was
induced by peroral infection of mice with T. gondii at day 0 as described
in methods. Survival of animals following prophylactic (Proph, black
line; n = 10) or therapeutic (Therap, gray line; n = 10) PACAP treatment
as compared to placebo controls (PLC, dotted line; n = 16) was
monitored twice daily until day 28 post infection (p.i.). Significance
levels (as compared to respective groups) were determined by Kaplan-
Meier analysis. Data are pooled from three independent experiments.
doi:10.1371/journal.pone.0108389.g001
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cells (Tregs) [14,20], we quantified ileal CD3+ and FOXP3+ cells.
Seven days following T. gondii infection, CD3+ T lymphocytes
increased multifold, but were less abundant in mice of either
PACAP treatment group as compared to PLC-treated animals
(p,0.005-0.0005; Fig. 3A). Conversely, FOXP3+ Treg numbers
decreased upon T. gondii infection. Following PACAP prophy-
laxis, however, ileal FOXP3+ cell numbers were approximately
50% higher as compared to PLC-treated control and short-term
PACAP-treated mice (p,0.05 and p,0.01, respectively; Fig. 3B).
Given that neutrophils, monocytes, and macrophages are pivotal
Figure 2. Amelioration of acute ileitis in PACAP-treated mice. Ileitis was induced by peroral infection of mice with T. gondii at day 0. (A)
Relative body weight loss of mice (in %), (B) relative small intestinal shortening (in %), and (C) histopathological scores of the terminal ileum following
PACAP prophylactic treatment (Proph, white bars), PACAP therapy (Therap, gray bars) or placebo application (black bar) at day 7 post infection.
Numbers of analyzed animals are given in parentheses. Mean values, standard errors of the mean, and significance levels as determined by the Mann-
Whitney-U test are indicated. Data are pooled from three independent experiments. (D) Representative photomicrographs (1006magnification; scale
bar 100 mm) of histopathological changes in ileal paraffin sections from three independent experiments are shown. Naı¨ve, uninfected mice served as
controls.
doi:10.1371/journal.pone.0108389.g002
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effector immune cells during acute ileitis development exerting
oxidative stress to the intestinal epithelium [25], we investigated
the recruitment of MPO7+ and F4/80+ cells in the small intestinal
lamina propria. Ileal numbers of neutrophils, monocytes, and
macrophages increased multifold upon ileitis development (p,
0.0001 vs. naive controls; Fig. 3C, D). At day 7 p.i., however,
mice subjected to prophylactic PACAP treatment exhibited lower
ileal MPO7+ cells as compared to mice with therapeutic PACAP
Figure 3. Intestinal immune cell responses following ileitis induction in PACAP-treated mice. Ileitis was induced by peroral infection of
mice with T. gondii at day 0. The average number of cells positive for (A) CD3 (T lymphocytes), (B) FOXP3 (regulatory T cells, Tregs), (C) MPO7
(myeloperoxidase-7, neutrophils and monocytes), and (D) F4/80 (macrophages) from at least six high power fields (HPF, 4006magnification) per
animal were determined microscopically in immunohistochemically stained ileum sections derived from mice following PACAP prophylactic
treatment (Proph, white bars), PACAP therapy (Therap, gray bars), or placebo application (black bar) at day 7 post infection as compared to naı¨ve
controls (lined bars). Numbers of analyzed animals are given in parentheses. Mean values, standard errors of the mean, and significance levels as
determined by the Mann-Whitney-U test are indicated. Data are pooled from three independent experiments.
doi:10.1371/journal.pone.0108389.g003
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or PLC treatment (p,0.05 and p,0.0001, respectively; Fig. 3C,
D). Notably, ileal F4/80+ cell numbers decreased in mice of both
PACAP groups as compared to PLC-treated control animals at
day 7 p.i. (p,0.0001; Fig. 3C, D).
To further unravel immune-modulatory properties of PACAP
treatment we determined mRNA expression levels of pro-
inflammatory cytokines in ex vivo ileal biopsies. IL-23p19 and
IL-22 mRNA were both up-regulated in the ileum 7 days
Figure 4. Pro-inflammatory cytokine responses in ilea of PACAP-treated mice. Ileitis was induced by peroral infection of mice with T. gondii
at day 0. (A) IL-23p19 and (B) IL-22 mRNA expression levels (by RT-PCR) as well as (C) IFN-c and (D) MCP-1 protein concentrations (by CBA) were
determined in ex vivo ileum biopsies obtained from mice following PACAP prophylactic treatment (Proph, white bars), PACAP therapy (Therap, gray
bars), or placebo application (black bars) at day 7 post infection as compared to naı¨ve animals (lined bars). mRNA expression levels are expressed as
fold changes relative to HPRT mRNA expression (Arbitrary Units). Numbers of analyzed animals are given in parentheses. Mean values, standard errors
of the mean, and significance levels as determined by the Mann-Whitney-U test are indicated. Data are pooled from three independent experiments.
doi:10.1371/journal.pone.0108389.g004
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following T. gondii infection (p,0.001 and p,0.01, respectively;
Fig. 4A, B). Upon PACAP prophylaxis, however, ileal IL-23p19,
acting as a main inducing factor within the Th1 inflammatory
cascade [19,25], was down-regulated (p,0.05; Fig. 4A), whereas
IL-22 mRNA levels tended to be lower as compared to PLC
treated mice at day 7 p.i. (n.s.; Fig. 4B). On protein level, ileal
IFN-c and MCP-1 concentrations were lower in ex vivo ileum
biopsies following PACAP prophylaxis as compared to PLC-
treated mice (p,0.05; Fig. 4C, D; Table 1), whereas local TNF-
a expression levels did not differ at day 7 p.i. (Table 1). The
diminished intestinal pro-inflammatory responses upon PACAP
application was further underlined by lower IFN-c and NO
protein concentrations measured in MLNs derived from mice
subjected to PACAP prophylaxis as compared to control animals
at day 7 p.i. (p,0.05 and p,0.005, respectively; Fig. 5;
Table 1). Notably, NO levels were also decreased in MLNs
following therapeutic PACAP as compared to PLC treatment (p,
0.001; Fig. 5B). Taken together, PACAP treatment ameliorates
T. gondii induced small intestinal Th1-type immune responses.
Diminished extra-intestinal pro-inflammatory immune
responses following PACAP application in acute ileitis
In the following we investigated whether potential extra-
intestinal T. gondii-induced sequelae were diminished following
PACAP treatment. To address this, we measured pro-inflamma-
tory cytokines in ex vivo biopsies derived from liver and kidneys of
infected and naı¨ve mice. Upon T. gondii infection, hepatic IFN-c,
TNF-a, MCP-1, and IL-6 protein levels increased multi-fold (p,
0.05-0.0001 vs naı¨ve mice; Fig. 6A–D). Respective pro-inflam-
matory cytokine concentrations, however, were lower in livers
following PACAP prophylaxis as compared to controls at day 7
p.i. (p,0.05-0.0005; Fig. 6A–D; Table 1). In addition, mice
from the PACAP prophylaxis group exhibited lower splenic TNF-
a levels as compared to PLC-treated controls at day 7 p.i. (p,0.05;
Fig. 6E; Table 1). Hence, PACAP dampens pro-inflammatory
responses in T. gondii induced acute ileitis not only locally but also
systemically affecting extra-intestinal compartments.
Up-regulated anti-inflammatory immune responses
following PACAP application in acute ileitis
We next investigated whether PACAP-induced anti-inflamma-
tory responses in the small intestine and extra-intestinal compart-
ments might have contributed to the improved outcome following
treatment of mice with the synthetic compound. Following
PACAP prophylaxis, mice displayed higher IL-4 protein levels in
ex vivo biopsies derived from MLNs and livers at day 7 p.i. as
compared to PLC treated mice (p,0.05; Fig. 7A, B; Table 1).
Remarkably, also systemic anti-inflammatory responses were up-
regulated in mice subjected to PACAP prophylaxis as indicated by
higher IL-10 protein levels in spleen and serum following long-
term PACAP as compared to PLC treatment at day 7 p.i. (p,0.05
and p,0.01, respectively; Fig. 7C, D; Table 1). In addition,
mice with therapeutic PACAP treatment displayed higher splenic
IL-10 concentrations as comparted to PLC-treated control
animals (p,0.005; Fig. 7C).
Significant beneficial extra-intestinal effects exerted by prophy-
lactic PACAP application were further supported by examination
of H&E-stained paraffin sections taken from lungs and kidneys at
day 7 p.i. (Fig. 8). Whereas lungs of PLC-treated mice suffering
from acute ileitis displayed significant peri-bronchial cuffs of
inflammatory cells and hemosiderin deposits therein, lungs
following PACAP prophylaxis appeared similar to those of
uninfected mice (Fig. 8A). Furthermore, pyknotic, degenerating
T
a
b
le
1
.
Su
m
m
ar
y
o
f
p
ro
-
an
d
an
ti
-i
n
fl
am
m
at
o
ry
m
e
d
ia
to
r
re
g
u
la
ti
o
n
fo
llo
w
in
g
p
ro
p
h
yl
ac
ti
c
P
A
C
A
P
ve
rs
u
s
p
la
ce
b
o
tr
e
at
m
e
n
t
at
d
ay
7
p
.i.
P
A
C
A
P
(p
ro
p
h
.)
V
s.
P
L
C
IF
N
-c
T
N
F
-a
M
C
P
-1
IL
-6
N
O
IL
-4
IL
-1
0
Ile
u
m
Y
)
Y
)
)
)
)
M
LN
Y
)
)
)
Y
X
)
Li
ve
r
Y
Y
Y
Y
)
X
)
Sp
le
e
n
)
Y
)
)
)
)
X
Se
ru
m
)
)
)
)
)
)
X
Y:
lo
w
e
r
)
:
co
m
p
ar
ab
le
X:
h
ig
h
e
r
le
ve
ls
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
8
3
8
9
.t
0
0
1
PACAP Ameliorates Acute Ileitis and Extraintestinal Sequelae
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e108389
and finally apoptotic glomeruli were observed in kidneys of PLC-,
but not PACAP-treated mice at day 7 p.i. (Fig. 8B). Noteworthy,
this is the first analysis of inflammatory sequelae affecting lungs
and kidneys in the T. gondii induced acute ileitis model.
Taken together, T. gondii infected mice subjected to a
prophylactic PACAP regimen did not only display less pro-
inflammatory Th1-type immunopathology within the ileum, but
also exerted beneficial extra-intestinal and systemic effects as
indicated by down-regulated pro- and up-regulated anti-inflam-
matory responses.
Discussion
A plethora of previous in vitro and in vivo studies revealed that
the neuropeptide PACAP acts as a pleiotropic immune-modulator
[31]. For the first time we investigated the immune-modulatory
properties of prophylactic and therapeutic synthetic PACAP
administration in murine T. gondii induced acute ileitis. Impor-
tantly, PACAP did not exhibit any anti-bacterial effects in vitro,
which might have directly interfered with intestinal microbiota
composition subsequently impacting disease outcome. Given that
anti-parasitic effects of PACAP and VIP against Trypanosoma
brucei were described previously [32,33], we started prophylactic
PACAP treatment one day following T. gondii infection in order
to minimize direct interference of the compound with the parasite
thereby counteracting the induction of inflammation. Notably,
ileal T. gondii DNA loads did not differ between the respective
treatment groups at day 7 p.i. Whereas control mice suffered from
acute pan-ileitis with necroses at day 7 p.i. and succumbed to
infection, PACAP treated mice were protected from ileal
immunopathology in a time-of-treatment dependent manner as
indicated by better clinical conditions, macroscopic aspects and
only minor small intestinal mucosal changes with preserved
epithelial lining due to PACAP prophylaxis. Our results are
supported by two previous studies demonstrating that DSS-
induced colitis was exacerbated in PACAP2/2 mice [8,9],
whereas the devastating phenotype could be rescued by intraper-
itoneal synthetic PACAP administration at day 1 following colitis
induction [9]. In our study, the better outcome following
prophylactic PACAP treatment was due to a dampened small
intestinal Th1-type immunopathology as indicated by a reduced
accumulation of T lymphocytes, the major driving forces of T.
gondii induced ileitis, in the ileal mucosa and lower local
expression of the key regulator IL-23p19 and pro-inflammatory
mediators such as IFN-c, nitric oxide, and the chemokine MCP-1.
Previous in vitro studies revealed that PACAP inhibits the
proliferation and migration of T lymphocytes and concomitant
Th1 cytokine release [3,34], and further acts as a ‘‘macrophages
inactivating factor’’ [35] given that pro-inflammatory cytokine
release by stimulated macrophages was reduced due to PACAP
action [36]. In line with this, numbers of recruited neutrophils,
monocytes, and macrophages were reduced in PACAP-treated
mice in our study, which in turn reduced oxidative stress to the
intestinal epithelium. Our data are further supported by a study
demonstrating a diminished influx of lymphocytes, neutrophils,
and macrophages into the peritoneal cavity of PACAP-treated
mice suffering from acute peritonitis [37]. Furthermore, prophy-
lactically PACAP-treated mice displayed higher numbers of ileal
Figure 5. Pro-inflammatory cytokine responses in mesenteric lymph nodes of PACAP-treated mice. Ileitis was induced by peroral
infection of mice with T. gondii at day 0. (A) IFN-c and (B) nitric oxide secretion were determined in overnight cultures of ex vivo biopsies derived from
mesenteric lymphnodes (MLNs) of mice following PACAP PACAP prophylactic treatment (Proph, white bars), PACAP therapy (Therap, gray bars), or
placebo application (black bars) at day 7 post infection as compared to naı¨ve animals (lined bars). Numbers of analyzed animals are given in
parentheses. Mean values, standard errors of the mean, and significance levels as determined by the Mann-Whitney-U test are indicated. Data are
pooled from three independent experiments.
doi:10.1371/journal.pone.0108389.g005
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FOXP3+ Tregs as compared to control mice at day 7 p.i. In
support of this, PACAP2/2 mice exhibited reduced numbers of
proliferating Tregs in experimental autoimmune encephalomyeli-
tis [38,39]. Interestingly, VIP and PACAP have been previously
shown to generate tolerogenic dendritic cells (DCs) subsequently
inducing functional Tregs in vitro and in vivo for maintaining
peripheral tolerance [40–42]. Hence, it is tempting to speculate
that the observed increase in ileal Tregs in prophylactically with
PACAP treated mice at day 7 p.i. was most likely due to the
PACAP-induced ‘‘tolerogenic DC – Treg axis’’ which might act as
one of the potential compensatory mechanisms to combat the
parasitic infection. In our study the dampened intestinal pro-
inflammatory responses exerted by PACAP prophylactic treat-
ment during acute ileitis were accompanied by an up-regulated
expression of the anti-inflammatory Th2-type cytokine IL-4 in
MLNs. In line with this, in vitro studies revealed that macrophages
treated with PACAP gained the ability to induce Th2-type
cytokines such as IL-4 and to inhibit Th1-type cytokine expression
levels in primed CD4+ T cells [43]. When antigen-immunized
mice were challenged with PACAP, decreased numbers of IFN-c
producing cells could be observed, whereas, conversely, IL-4
secreting cells increased [43].
Remarkably, PACAP-induced anti-inflammatory effects were
not restricted to the small intestine in our study, but could also be
observed at extra-intestinal locations such as liver, kidneys, and
lungs. T. gondii infected mice suffering from acute ileitis were
previously shown to display an increased hepatic abundance of
activated CD4+ T cells [21] and increased levels of pro-
inflammatory cytokines such as TNF-a, IFN-c, MCP-1, IL-6 in
the liver as shown in our very recent [44]) and actual study.
However, histopathological changes in lungs and kidneys of T.
gondii infected mice with acute ileitis have not been reported yet.
Figure 6. Pro-inflammatory cytokine responses in extra-intestinal compartments of PACAP-treated mice. Ileitis was induced by peroral
infection of mice with T. gondii at day 0. Hepatic (A) IFN-c, (B) TNF-a, (C) MCP-1, (D) IL-6, and (E) splenic TNF-a secretion were determined in overnight
cultures of ex vivo biopsies derived from respective organs of mice following PACAP PACAP prophylactic treatment (Proph, white bars), PACAP
therapy (Therap, gray bars), or placebo application (black bars) at day 7 post infection as compared to naı¨ve animals (lined bars). Numbers of analyzed
animals are given in parentheses. Mean values, standard errors of the mean, and significance levels as determined by the Mann-Whitney-U test are
indicated. Data are pooled from three independent experiments.
doi:10.1371/journal.pone.0108389.g006
PACAP Ameliorates Acute Ileitis and Extraintestinal Sequelae
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e108389
Seven days following T. gondii infection, peri-bronchial cuffs
consisting of leukocytes with hemosiderin deposits therein (most
likely due to hemosiderin-laden macrophages) could be observed
in lungs, whereas in kidneys of diseased mice glomeruli were
pyknotic, degenerating and apoptotic and the Bowman capsule
enlarged indicative for severe renal dysfunction. It is well known
Figure 7. Anti-inflammatory cytokine responses in extra-intestinal compartments of PACAP-treated mice. Ileitis was induced by
peroral infection of mice with T. gondii at day 0. IL-4 protein levels were determined in ex vivo biopsies of (A) mesenteric lymph nodes (MLN) and (B)
liver, and IL-10 concentrations measured in (C) spleen and (D) serum of mice following PACAP prophylactic treatment (Proph, white bars), PACAP
therapy (Therap, gray bars), or placebo application (black bars) at day 7 post infection as compared to naı¨ve animals (lined bars). Numbers of analyzed
animals are given in parentheses. Mean values, standard errors of the mean, and significance levels as determined by the Mann-Whitney-U test are
indicated. Data are pooled from three independent experiments.
doi:10.1371/journal.pone.0108389.g007
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that during acute ileitis viable commensal intestinal bacterial
species such as E. coli can translocate through the compromised
epithelial cell barrier into the intestinal lamina propria, and
subsequently come in contact with immune cells thereby further
exacerbating the inflammatory scenario [27,45]. When translo-
cated bacteria or their cell wall constituents such as LPS reach the
blood stream, sepsis and subsequent multiple organ failure with
fatal consequences occur [27]. Hence, it is remarkable that
following PACAP prophylaxis the observed histopathological
changes leading to organ failure could be prevented in our study.
The extra-intestinal immune-modulatory properties of PACAP
were characterized by lower extra-intestinal and systemic expres-
sion of pro-inflammatory cytokines whereas anti-inflammatory
cytokines such as IL-4 in liver and systemic IL-10 levels measured
in serum and spleen were higher in mice subjected to PACAP
prophylaxis. Previous in vitro studies revealed that PACAP
inhibits the production of pro-inflammatory mediators by LPS-
stimulated macrophages, whereas IL-10 release was enforced
[43,46,47]. In line with our extra-intestinal results demonstrating
ameliorated hepatic, renal and pulmonal inflammatory responses
in T. gondii infected mice with prophylactic PACAP treatment,
PACAP has been shown to protect against renal damage in
different renal injury models [47–51] and against murine liver
ischemia and oxidative stress [51,52]. Furthermore, PACAP exerts
significant anti-inflammatory effects in endotoxin-induced acute
pulmonal inflammation [53]. Due to the anti-inflammatory and
broncho-relaxant properties, synthetic PACAP analogues have
been developed for treatment of bronchial asthma [53,54].
Moreover, PACAP has been shown to inhibit TLR-4 activation
during experimental traumatic brain injury [55]. Given that the
immunopathology underlying acute T. gondii induced ileitis is
initiated and perpetuated by bacterial LPS via TLR-4-dependent
signaling [22,23], dampening of TLR-4 dependent signaling
reveals an important key stone of mechanism by which PACAP
exerts its multi-facetted beneficial effect. In line with this, PACAP
proved effective in preventing experimental endotoxin sepsis and
shock [47,56,57].
It is noteworthy that 20% of mice even survived the acute
disease for more than 4 weeks when treated prophylactically with
PACAP, whereas all control animals had died by day 9.5 p.i. But
that time, however, 40% and 80% of mice from the therapeutic
and prophylactic PACAP treatment groups, respectively, were still
alive. The long-term survival effect upon PACAP prophylaxis is
remarkable given that the duration of prophylactic treatment was
relatively short since the synthetic compound was applied for only
six days in total and withdrawn by day 7 p.i. Furthermore, the
biological impact of PACAP-induced beneficial effects becomes
more plausible in such a devastating model. It is tempting to
speculate that the survival rates would have been even higher if
PACAP had been administered further on and not withdrawn by
day 6 p.i. One should take into account that when considering a
synthetic compound for combating systemic inflammatory disease
in humans (irrespective of its etiology), not a single molecule but
rather a plethora of molecules involved in the signaling cascade of
the hyper-inflammatory scenario should be targeted [47]. Hence,
PACAP seems a promising candidate in this regard.
In conclusion, synthetic PACAP ameliorates intestinal and
systemic inflammation following T. gondii induced acute ileitis in a
duration-of-treatment dependent manner and hence provides an
alternative option for prophylaxis and treatment of intestinal
inflammation such as inflammatory bowel diseases.
Supporting Information
Figure S1 Comparable ileal T. gondii DNA loads in
PACAP and placebo treated mice. Ileitis was induced by
peroral infection of mice with T. gondii at day 0. Parasitic DNA
levels were determined in ileal ex vivo biopsies following PACAP
prophylactic treatment (Proph, white bars), PACAP therapy
(Therap, gray bars) or placebo application (black bar) at day 7
post infection by quantitative real time PCR. Numbers of analyzed
animals are given in parentheses. Mean values and standard errors
of the mean are indicated. Data are pooled from three
independent experiments.
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Figure 8. Less severe extra-intestinal histopathology following
PACAP prophylaxis. Paraffin section of (A) lung and (B) kidney
samples were obtained from naı¨ve animals (right panel) and from mice
following PACAP prophylactic treatment (PACAP, middle panel) and
compared to placebo controls (PLC, left panel) at day 7 post infection.
Representative photomicrographs of H&E stained paraffin sections
(upper panel: 1006magnification; scale bar 100 mm; lower panel: 4006
magnification; scale bar 20 mm) from three independent experiments
are shown. White arrow head points towards hemosiderin deposit (in
A), black arrows indicate an inflammatory peri-bronchial cuff (in A) and
a pyknotic, degenerated, apoptotic glomerulum (in B).
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